(Fluoro)quinolone prescriptions for upper respiratory tract infections in the German outpatient sector: a health insurance claims analysis
GMS Infectious Diseases · 27.05.2025 · 13 (Doc01) · Doc01-Doc01
DOI: 10.3205/id000091 ↗Kurz gefasst
Fachartikel in der Zeitschrift GMS Infectious Diseases, erschienen am 27.05.2025. Verfasst von Birgit Arens und 5 weiteren Autor:innen. Beteiligte Einrichtung: Kompetenz-Centrum Qualitätssicherung, Medizinischer Dienst Baden-Württemberg, Lahr, Germany. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Acute upper respiratory tract infections (URTIs) are frequent causes of medical treatment by general practitioners (GPs). In general, these are viral and self-limiting illnesses, but antibiotics are prescribed. In Germany, fluoroquinolones are not authorised for the indications pharyngitis, laryngitis, tonsillitis and acute bronchitis due to possible serious side effects. This analysis looks at fluoroquinolone prescriptions for URTI by GPs in 2022.
Methods
Frequency of fluoroquinolone prescriptions were analysed at case level and regionally using administrative insurance data from the German health insurance company BARMER. We included patients treated in GP practices without relevant concomitant diseases.
Results
In 2022, 25% (1,197,568/4,720,786) of insured persons with upper respiratory tract infections (URTI) were prescribed antibiotics. After excluding comorbidities and other risk factors such as previous hospitalisation, the prescription rate for uncomplicated URTIs was calculated to be 6% (80,786/1,365,646). Fluoroquinolones were given in 2.4% of antibiotic prescriptions (1,951/80,786). Nationwide, 3.7% of the GPs prescribed fluoroquinolones, most frequently in the region Brandenburg with 6.6% (74/1,121).
Conclusion
This analysis showed that fluoroquinolones are still prescribed for uncomplicated URTI, which must be considered as alarming regarding the nature of the disease and the unfavourable risk-benefit profiles. There were clear regional differences in fluoroquinolone prescribing, indicating potential for improvement in the use of reserve antibiotics for uncomplicated upper respiratory tract infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kompetenz-Centrum Qualitätssicherung, Medizinischer Dienst Baden-Württemberg, Lahr, Germany.
- Barmer Institut für Gesundheitssystemforschung, Medizin und Versorgungsforschung, Berlin, Germany.
- Vivantes Netzwerk für Gesundheit GmbH, Head of Translationale Forschung, Lehre und Kooperation, Berlin, Germany.
Zitieren
APA
Arens, B., L'hoest, H., Wolf, A., Hennig, B., Marschall, U., & Nachtigall, I. (2025). (Fluoro)quinolone prescriptions for upper respiratory tract infections in the German outpatient sector: a health insurance claims analysis. GMS Infectious Diseases, 13(Doc01), Doc01-Doc01. https://doi.org/10.3205/id000091
Vancouver
Arens B, L'hoest H, Wolf A, Hennig B, Marschall U, Nachtigall I. (Fluoro)quinolone prescriptions for upper respiratory tract infections in the German outpatient sector: a health insurance claims analysis. GMS Infectious Diseases. 2025;13(Doc01):Doc01-Doc01. doi:10.3205/id000091
BibTeX
@article{Arens2025,
author = {Arens, Birgit and L'hoest, Helmut and Wolf, Alissa and Hennig, Beata and Marschall, Ursula and Nachtigall, Irit},
title = {(Fluoro)quinolone prescriptions for upper respiratory tract infections in the German outpatient sector: a health insurance claims analysis},
journal = {GMS Infectious Diseases},
year = {2025},
volume = {13},
number = {Doc01},
pages = {Doc01--Doc01},
doi = {10.3205/id000091}
}
EUVIMED